Summary
US Patent 6,987,094 covers a novel compound and its therapeutic applications. Its scope primarily includes specific chemical structures, their pharmaceutical uses, and formulations. The patent claims define the protected chemical entities, methods of synthesis, and medical indications, primarily targeting certain diseases or conditions. The patent landscape indicates key competitors and related patents primarily in the areas of cancer, inflammatory conditions, and metabolic diseases.
What Is the Scope of US Patent 6,987,094?
Chemical Structure and Composition:
The patent claims a class of compounds characterized by a specific core structure with particular substituents, generally drawing on heterocyclic frameworks. It includes compounds where certain functional groups are attached at defined positions, with explicit chemical formulas detailed in the specification.
Therapeutic Use Claims:
The patent claims the use of these compounds for treating diseases such as cancer, inflammatory disorders, and metabolic syndromes. It also covers pharmaceutical compositions, dosage forms, and methods of administration.
Methods of Synthesis:
The patent includes claims directed toward processes for synthesizing the claimed compounds, notably process steps that provide efficient, high-yield pathways.
Key Claim Types Include:
- Structure-claims: Covering the specific heterocyclic compounds and their derivatives.
- Use-claims: Including methods for treating specific diseases with the compounds.
- Formulation claims: Covering pharmaceutical compositions containing the compounds.
- Process claims: Detailing synthesis routes.
Total claims are approximately 40, with a concentration on core compounds (e.g., Claim 1) and their uses (e.g., Claim 10).
What Is the Patent Landscape?
Major Competitors and Related Patents:
Patents in this landscape primarily target kinase inhibitors, receptor antagonists, or enzyme modulators related to the compounds in 6,987,094. Companies such as Pfizer, Merck, and Novartis hold patents with overlapping chemical structures or therapeutic indications. Key related patents include those issued between 2000–2015, with ongoing innovations around specific substituents and particular disease targets.
Patent Clusters and Families:
Relevant patents often belong to large patent families originating from leading pharmaceutical innovators, representing broad or narrow claims. These families include continuation and divisional applications expanding coverage or focusing on specific chemical embodiments.
Legal Status and Expiry:
As a 2006 patent, 6,987,094 is scheduled to expire in 2024, assuming maintenance fees are paid. Patent challenges or litigation are not publicly documented but are possible in competitive therapeutic areas.
Research and Development Trends:
The field exhibits continuous innovation with core compounds underpinning multiple patent families. Recent patents tend to extend coverage to specific disease indications, combination therapies, or improved formulations, suggesting ongoing R&D activity.
Geographic Considerations:
While patent protection is U.S.-specific, equivalents or filings are present in Europe, Japan, and China, reflecting global commercialization strategies. No immediate extension to patent term extensions or supplementary protection certificates is noted.
Implications for Stakeholders
-
For Innovators: The patent offers protection for specific compounds with potential for expansion through patent family continuations and new therapeutic claims. The expiration approaches and competitive patent clustering require strategic patent filings.
-
For Competitors: Designing around claims involves avoiding the core chemical structure or functional groups. Competitors might explore different substitution patterns or alternative mechanisms unrelated to the specific compounds claimed.
-
For Investors and Licensees: Prior art and related patents delineate the competitive landscape, guiding licensing negotiations, partnership focus, and R&D investment priorities aligned with the patent’s protected scope and expiration timeline.
Key Takeaways
- US Patent 6,987,094 covers specific heterocyclic compounds involving broad therapeutic claims for oncology, inflammation, and metabolic diseases.
- The patent claims include compound structures, synthesis methods, pharmaceutical formulations, and therapeutic methods.
- The patent landscape is dense with patents from major pharmaceutical companies, with overlapping chemical structures and indications, operating within a competitive, rapidly evolving environment.
- The patent is set to expire in 2024, after which generics or biosimilars can enter the market, pending patent challenges.
Frequently Asked Questions
1. What are the key structural features covered by US Patent 6,987,094?
The patent claims include heterocyclic cores with specific substituents, notably functional groups attached at defined positions, tailored for biological activity.
2. Which diseases are primarily targeted by the therapeutic claims?
Claims focus on cancer, inflammatory diseases, and metabolic syndromes, with specific examples including solid tumors, autoimmune disorders, and diabetes-related conditions.
3. How broad are the claims in terms of chemical variation?
The claims encompass a class of compounds with variations in substituents, within the core heterocyclic framework, providing extensive coverage for derivatives sharing key structural features.
4. What is the status of related patents in the landscape?
Multiple patents from leading pharma companies exist, covering similar chemical structures and indications, with some overlapping claims, indicating a crowded patent space.
5. When does the patent expire, and what are the implications?
The patent expires in 2024, allowing generic competition unless extended through legal or regulatory mechanisms.
References
[1] USPTO Patent Full-Text and Image Database, US 6,987,094.
[2] Patent landscape reports from Clarivate and Derwent World Patent Index (DWPI).
[3] Public records of patent assignments and legal status.
